<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Consilium Medicum</journal-id><journal-title-group><journal-title xml:lang="en">Consilium Medicum</journal-title><trans-title-group xml:lang="ru"><trans-title>Consilium Medicum</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Consilium Medicum</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-1753</issn><issn publication-format="electronic">2542-2170</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">634845</article-id><article-id pub-id-type="doi">10.26442/20751753.2024.5.202877</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Known and unknown hymecromone. A review</article-title><trans-title-group xml:lang="ru"><trans-title>Известный и неизвестный гимекромон</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6150-1808</contrib-id><name-alternatives><name xml:lang="en"><surname>Plotnikova</surname><given-names>Ekaterina Yu.</given-names></name><name xml:lang="ru"><surname>Плотникова</surname><given-names>Екатерина Юрьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>д-р мед. наук, проф. каф. поликлинической терапии, постдипломной подготовки врачей и сестринского дела, рук. курса клинической гастроэнтерологии</p></bio><email>eka-pl@rambler.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kemerovo State Medical University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО «Кемеровский государственный медицинский университет» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-08-05" publication-format="electronic"><day>05</day><month>08</month><year>2024</year></pub-date><volume>26</volume><issue>5</issue><issue-title xml:lang="en">Gastroenterology</issue-title><issue-title xml:lang="ru">Гастроэнтерология</issue-title><fpage>324</fpage><lpage>330</lpage><history><date date-type="received" iso-8601-date="2024-08-04"><day>04</day><month>08</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2024-08-04"><day>04</day><month>08</month><year>2024</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://consilium.orscience.ru/2075-1753/article/view/634845">https://consilium.orscience.ru/2075-1753/article/view/634845</self-uri><abstract xml:lang="en"><p>Hymecromone (4-MU) is a recognized agent currently used in clinical practice. Since 1960, hymecromone has been used in many countries as a choleretic and cholespasmolytic, a drug approved for use in humans with biliary tract disorders. The review presents both traditional European and Russian studies of the selective antispasmodic and choleretic properties of hymecromone, due to which hymecromone is the drug of choice for the treatment of biliary tract diseases, as well as new fundamental and clinical studies of numerous pleiotropic effects of 4-MU associated with inhibition of hyaluronic acid and many other properties of this exciting molecule. These include antibacterial, antiviral, and nonspecific anti-inflammatory effects. Positive results have been demonstrated in carbohydrate and lipid metabolism disorders, autoimmune diseases, as well as liver, heart, and kidney diseases. Numerous in vitro and in vivo studies have been presented in pancreatic, prostate, skin, esophagus, breast, liver, ovary, bone cancers, metastatic lesions, leukemia, autoimmune and inflammatory diseases. Hymecromone is indicated not only as a choleretic and cholespasmolytic but also as a choleseptic in cholangitis and chronic cholecystitis, including opisthorchiasis, which does not disagree with its label. Odecromone® (hymecromone, tablets 200 mg) is available on the Russian market; it replaced the originator drug and is its fully equivalent generic.</p></abstract><trans-abstract xml:lang="ru"><p>Гимекромон (4-MU) является признанным средством, применяемым в настоящее время в клинической практике. С 1960 г. гимекромон используют во многих странах как холеретик и холеспазмолитик, это одобренный для применения у людей при патологии билиарного тракта препарат. В обзоре представлены как традиционные европейские и отечественные исследования селективного спазмолитического и желчегонного свойств гимекромона, благодаря которым гимекромон является препаратором выбора для лечения заболеваний желчевыводящих путей, так и новые фундаментальные и клинические исследования многочисленных плейотропных эффектов 4-MU, связанных с ингибированием гиалуроновой кислоты и многими другими свойствами этой интересной молекулы. К ним относятся антибактериальные, противовирусные и неспецифические противовоспалительные эффекты. Продемонстрированы положительные результаты при нарушениях углеводного и липидного обменах, при аутоиммунных заболеваниях, болезнях печени, сердца, почек. Представлены многочисленные исследования in vitro и in vivo при раках поджелудочной железы, предстательной железы, кожи, пищевода, молочной железы, печени, яичников, костей, при метастатических поражениях, лейкемии, аутоиммунных и воспалительных заболеваниях. Показано назначение гимекромона не только в качестве холеретика и холеспазмолитика, но и как холесептика при холангитах, хронических холециститах, в том числе при описторхозе, что не противоречит его инструкции. На отечественном фармацевтическом рынке представлен препарат с гимекромоном – Одекромон® (таблетки 200 мг), который «пришел» на смену оригинальному препарату и является его полноценным генериком.</p></trans-abstract><kwd-group xml:lang="en"><kwd>hymecromone</kwd><kwd>choleretic</kwd><kwd>cholespasmolytic</kwd><kwd>biliary tract dysfunction</kwd><kwd>gallstone disease</kwd><kwd>postcholecystectomy syndrome</kwd><kwd>hyaluronic acid</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>гимекромон</kwd><kwd>холеретик</kwd><kwd>холеспазмолитик</kwd><kwd>дисфункция желчевыводящих путей</kwd><kwd>желчнокаменная болезнь</kwd><kwd>постхолецистэктомический синдром</kwd><kwd>гиалуроновая кислота</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>ChemBK. Available at: https://www.chembk.com/en/chem/7-Hydroxy-4-methyl-2H-1-benzopyran-2-one. Accessed: 26.06.24.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Garrett ER, Venitz J. Comparisons of detections, stabilities, and kinetics of degradation of hymecromone and its glucuronide and sulfate metabolites. J Pharm Sci. 1994;83(1):115-6. DOI:10.1002/jps.2600830128</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Garrett ER, Venitz J, Eberst K, Cerda JJ. Pharmacokinetics and bioavailabilities of hymecromone in human volunteers. Biopharm Drug Dispos. 1993;14(1):13-39. DOI:10.1002/bdd.2510140103</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Nagy N, Kuipers HF, Frymoyer AR, et al. 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol. 2015;6:123. DOI:10.3389/fimmu.2015.00123</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Hoffmann RM, Schwarz G, Pohl C, et al. Gallensäure-unabhängige Wirkung von Hymecromon auf die Gallesekretion und die Motilität der Gallenwege [Bile acid-independent effect of hymecromone on bile secretion and common bile duct motility]. Dtsch Med Wochenschr. 2005;130(34–35):1938-43 [Article in German]. DOI:10.1055/s-2005-872606</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Минушкин О.Н. Одестон в лечении больных билиарной дисфункцией. Фарматека. 2010;(2):61-5 [Minushkin ON. Odeston v lechenii bol'nykh biliarnoi disfunktsiei. Farmateka. 2010;(2):61-5 (in Russian)].</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Яковенко Э.П., Агафонова Н.А., Кальнова С.Б. Одестон в терапии заболеваний билиарного тракта. Практикующий врач. 2001;19(1):30-2 [Iakovenko EP, Agafonova NA, Kal'nova SB. Odeston v terapii zabolevanii biliarnogo trakta. Praktikuiushchii Vrach. 2001;19(1):30-2 (in Russian)].</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Максимов В.А., Бунтин С.Е., Бунтина В.Г., и др. О влиянии гимекромона на моторную функцию билиарного тракта у больных с постхолецистэктомическим синдромом. Лечащий врач. 2008;(2):76-7 [Maksimov VA, Buntin SE, Buntina VG, et al. O vliianii gimekromona na motornuiu funktsiiu biliarnogo trakta u bol'nykh s postkholetsistektomicheskim sindromom. Lechashchii Vrach. 2008;(2):76-7 (in Russian)].</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Барышникова Н.B., Соусова Я.В. Эффективность монотерапии Гимекромоном-СЗ в лечении пациентов с различной патологией билиарного тракта. Медицинский алфавит. 2021;(40):14-20 [Baryshnikova NV, Sousova YaV. Effectiveness of Hymecromone monotherapy in treatment of patients with various pathologies of biliary tract. Medical Alphabet. 2021;(40):14-20 (in Russian)]. DOI:10.33667/2078-5631-2021-40-14-20</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Никитин И.Г., Саликов А.В., Федоров И.Г., Ильченко Л.Ю. Монотерапия гимекромоном пациентов с патологией билиарного тракта: клиническая эффективность и профиль безопасности. Лечебное дело. 2023;(3):34-40 [Nikitin IG, Salikov AV, Fedorov IG, Ilchenko LYu. Hymecromone Monotherapy in Patients with Biliary Tract Disorders: Clinical Efficacy and Safety Profile. Lechebnoe Delo. 2023;(3):34-40 (in Russian)].</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Бордин Д.С., Дубцова Е.А., Селезнева Э.Я., и др. Эффективность и безопасность различных доз гимекромона у больных, перенесших холецистэктомию. Эффективная фармакотерапия. 2021;17(39):34-8 [Bordin DS, Dubtsova EA, Selezneva EYa, et al. Efficacy and Safety of Hymecromone Various Doses in Patients Who Have Undergone Cholecystectomy. Effektivnaia Farmakoterapiia. 2021;17(39):34-8 (in Russian)]. DOI:10.33978/2307-3586-2021-17-39-34-38</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Поленов А.М., Погромов А.П. Гимекромон (одестон) в терапии больных с постхолецистэктомической дисфункцией сфинктера Одди. Экспериментальная и клиническая гастроэнтерология. 2003;(5):163-4 [Polenov AM, Pogromov AP. Gimekromon (odeston) v terapii bol'nykh s postkholetsistektomicheskoi disfunktsiei sfinktera Oddi. Eksperimental'naia i Klinicheskaia Gastroenterologiia. 2003;(5):163-4 (in Russian)].</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Охлобыстин А.В., Татаркина М.А., Охлобыстина О.З., и др. Эффективность применения препарата гимекромон при билиарном панкреатите. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2019;29(5):26-35 [Okhlobystin AV, Tatarkina MA, Okhlobystina OZ, et al. Hymecromone Efficacy in the Treatment of Biliary Pancreatitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2019;29(5):26-35 (in Russian)]. DOI:10.22416/1382-4376-2019-29-5-26-35</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Максимов В.А., Бунтин С.Е., Бунтина В.Г. Эффективность Одестона в лечении больных хроническим панкреатитом. Фарматека. 2009;13:72-4 [Maksimov VA, Buntin SE, Buntina VG. Effektivnost' Odestona v lechenii bol'nykh khronicheskim pankreatitom. Farmateka. 2009;13:72-4 (in Russian)].</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Goth A. The antibacterial properties of dicumarol. Science. 1945;101(2624):383. DOI:10.1126/science.101.2624.383</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Melliou E, Magiatis P, Mitaku S, et al. Natural and synthetic 2,2-dimethylpyranocoumarins with antibacterial activity. J Nat Prod. 2005;68(1):78-82. DOI:10.1021/np0497447</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Kawase M, Varu B, Shah A, et al. Antimicrobial activity of new coumarin derivatives. Arzneimittelforschung. 2001;51(1):67-71. DOI:10.1055/s-0031-1300004</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>El-Attar MS, Sadeek SA, Abd El-Hamid SM, Elshafie HS. Spectroscopic Analyses and Antimicrobial Activity of Novel Ciprofloxacin and 7-Hydroxy-4-methylcoumarin, the Plant-Based Natural Benzopyrone Derivative. Int J Mol Sci. 2022;23(14):8019. DOI:10.3390/ijms23148019</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Singh LK, Priyanka, Singh V, Katiyar D. Design, synthesis and biological evaluation of some new coumarin derivatives as potential antimicrobial agents. Med Chem. 2015;11(2):128-34. DOI:10.2174/1573406410666140902110452</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>McKallip RJ, Ban H, Uchakina ON. Treatment with the hyaluronic Acid synthesis inhibitor 4-methylumbelliferone suppresses LPS-induced lung inflammation. Inflammation. 2015;38(3):1250-9. DOI:10.1007/s10753-014-0092-y</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Barnes HW, Demirdjian S, Haddock NL, et al. Hyaluronan in the pathogenesis of acute and post-acute COVID-19 infection. Matrix Biol. 2023;116:49-66. DOI:10.1016/j.matbio.2023.02.001</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>McKallip RJ, Hagele HF, Uchakina ON. Treatment with the hyaluronic acid synthesis inhibitor 4-methylumbelliferone suppresses SEB-induced lung inflammation. Toxins (Basel). 2013;5(10):1814-26. DOI:10.3390/toxins5101814</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Arai E, Nishida Y, Wasa J, et al. Inhibition of hyaluronan retention by 4-methylumbelliferone suppresses osteosarcoma cells in vitro and lung metastasis in vivo. Br J Cancer. 2011;105(12):1839-49. DOI:10.1038/bjc.2011.459</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Collum SD, Chen NY, Hernandez AM, et al. Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis. Br J Pharmacol. 2017;174(19):3284-301. DOI:10.1111/bph.13947</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Collum SD, Molina JG, Hanmandlu A, et al. Adenosine and hyaluronan promote lung fibrosis and pulmonary hypertension in combined pulmonary fibrosis and emphysema. Dis Model Mech. 2019;12(5):dmm038711. DOI:10.1242/dmm.038711</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Yang S, Ling Y, Zhao F, et al. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. Signal Transduct Target Ther. 2022;7(1):91. DOI:10.1038/s41392-022-00952-w</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Jiang D, Liang J, Noble PW. Hyaluronan as an immune regulator in human diseases. Physiol Rev. 2011;91(1):221-64. DOI:10.1152/physrev.00052.2009</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Itano N, Atsumi F, Sawai T, et al. Abnormal accumulation of hyaluronan matrix diminishes contact inhibition of cell growth and promotes cell migration. Proc Natl Acad Sci U S A. 2002;99(6):3609-14. DOI:10.1073/pnas.052026799</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Ruppert SM, Hawn TR, Arrigoni A, et al. Tissue integrity signals communicated by high-molecular weight hyaluronan and the resolution of inflammation. Immunol Res. 2014;58(2-3):186-92. DOI:10.1007/s12026-014-8495-2</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Stern R, Asari AA, Sugahara KN. Hyaluronan fragments: an information-rich system. Eur J Cell Biol. 2006;85(8):699-715. DOI:10.1016/j.ejcb.2006.05.009</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Laurent TC, Laurent UB, Fraser JR. The structure and function of hyaluronan: An overview. Immunol Cell Biol. 1996;74(2):A1-7. DOI:10.1038/icb.1996.32</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Scott JE. Supramolecular organization of extracellular matrix glycosaminoglycans, in vitro and in the tissues. FASEB J. 1992;6(9):2639-45.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Tasanarong A, Khositseth S, Thitiarchakul S. The mechanism of increased vascular permeability in renal ischemic reperfusion injury: potential role of angiopoietin-1 and hyaluronan. J Med Assoc Thai. 2009;92(9):1150-8.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Khan AI, Kerfoot SM, Heit B, et al. Role of CD44 and hyaluronan in neutrophil recruitment. J Immunol. 2004;173(12):7594-601. DOI:10.4049/jimmunol.173.12.7594</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Evanko SP, Potter-Perigo S, Bollyky PL, et al. Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol. 2012;31(2):90-100. DOI:10.1016/j.matbio.2011.10.004</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Powell JD, Horton MR. Threat matrix: low-molecular-weight hyaluronan (HA) as a danger signal. Immunol Res. 2005;31(3):207-18. DOI:10.1385/IR:31:3:207</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Tesar BM, Jiang D, Liang J, et al. The role of hyaluronan degradation products as innate alloimmune agonists. Am J Transplant. 2006;6(11):2622-35. DOI:10.1111/j.1600-6143.2006.01537.x</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Termeer C, Benedix F, Sleeman J, et al. Oligosaccharides of Hyaluronan activate dendritic cells via toll-like receptor 4. J Exp Med. 2002;195(1):99-111. DOI:10.1084/jem.20001858</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Bollyky PL, Wu RP, Falk BA, et al. ECM components guide IL-10 producing regulatory T-cell (TR1) induction from effector memory T-cell precursors. Proc Natl Acad Sci U S A. 2011;108(19):7938-43. DOI:10.1073/pnas.1017360108</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Horton MR, Burdick MD, Strieter RM, et al. Regulation of hyaluronan-induced chemokine gene expression by IL-10 and IFN-gamma in mouse macrophages. J Immunol. 1998;160(6):3023-30.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Scheibner KA, Lutz MA, Boodoo S, et al. Hyaluronan fragments act as an endogenous danger signal by engaging TLR2. J Immunol. 2006;177(2):1272-81. DOI:10.4049/jimmunol.177.2.1272</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Zheng L, Riehl TE, Stenson WF. Regulation of colonic epithelial repair in mice by Toll-like receptors and hyaluronic acid. Gastroenterology. 2009;137(6):2041-51. DOI:10.1053/j.gastro.2009.08.055</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Gao F, Liu Y, He Y, et al. Hyaluronan oligosaccharides promote excisional wound healing through enhanced angiogenesis. Matrix Biol. 2010;29(2):107-16. DOI:10.1016/j.matbio.2009.11.002</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Gao F, Koenitzer JR, Tobolewski JM, et al. Extracellular superoxide dismutase inhibits inflammation by preventing oxidative fragmentation of hyaluronan. J Biol Chem. 2008;283(10):6058-66. DOI:10.1074/jbc</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Rilla K, Pasonen-Seppänen S, Rieppo J, et al. The hyaluronan synthesis inhibitor 4-methylumbelliferone prevents keratinocyte activation and epidermal hyperproliferation induced by epidermal growth factor. J Invest Dermatol. 2004;123(4):708-14. DOI:10.1111/j.0022-202X.2004.23409.x</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>Kultti A, Pasonen-Seppänen S, Jauhiainen M, et al. 4-Methylumbelliferone inhibits hyaluronan synthesis by depletion of cellular UDP-glucuronic acid and downregulation of hyaluronan synthase 2 and 3. Exp Cell Res. 2009;315(11):1914-23. DOI:10.1016/j.yexcr.2009.03.002</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Yoshihara S, Kon A, Kudo D, et al. A hyaluronan synthase suppressor, 4-methylumbelliferone, inhibits liver metastasis of melanoma cells. FEBS Lett. 2005;579(12):2722-6. DOI:10.1016/j.febslet.2005.03.079</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Clarkin CE, Allen S, Wheeler-Jones CP, et al. Reduced chondrogenic matrix accumulation by 4-methylumbelliferone reveals the potential for selective targeting of UDP-glucose dehydrogenase. Matrix Biol. 2011;30(3):163-8. DOI:10.1016/j.matbio.2011.01.002</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Nakazawa H, Yoshihara S, Kudo D, et al. 4-methylumbelliferone, a hyaluronan synthase suppressor, enhances the anticancer activity of gemcitabine in human pancreatic cancer cells. Cancer Chemother Pharmacol. 2006;57(2):165-70. DOI:10.1007/s00280-005-0016-5</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Saito T, Tamura D, Nakamura T, et al. 4-methylumbelliferone leads to growth arrest and apoptosis in canine mammary tumor cells. Oncol Rep. 2013;29(1):335-42. DOI:10.3892/or.2012.2100</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>García-Vilas JA, Quesada AR, Medina MÁ. 4-methylumbelliferone inhibits angiogenesis in vitro and in vivo. J Agric Food Chem. 2013;61(17):4063-71. DOI:10.1021/jf303062h</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Vigetti D, Rizzi M, Viola M, et al. The effects of 4-methylumbelliferone on hyaluronan synthesis, MMP2 activity, proliferation, and motility of human aortic smooth muscle cells. Glycobiology. 2009;19(5):537-46. DOI:10.1093/glycob/cwp022</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Saga R, Matsuya Y, Takahashi R, et al. 4-Methylumbelliferone administration enhances radiosensitivity of human fibrosarcoma by intercellular communication. Sci Rep. 2021;11(1):8258. DOI:10.1038/s41598-021-87850-3</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Díaz M, Pibuel M, Paglilla N, et al. 4-Methylumbelliferone induces antitumor effects independently of hyaluronan synthesis inhibition in human acute leukemia cell lines. Life Sci. 2021;287:120065. DOI:10.1016/j.lfs.2021.120065</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Weiz G, Molejon MI, Malvicini M, et al. Glycosylated 4-methylumbelliferone as a targeted therapy for hepatocellular carcinoma. Liver Int. 2022;42(2):444-57. DOI:10.1111/liv.15084</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Piccioni F, Fiore E, Bayo J, et al. 4-methylumbelliferone inhibits hepatocellular carcinoma growth by decreasing IL-6 production and angiogenesis. Glycobiology. 2015;25(8):825-35. DOI:10.1093/glycob/cwv023</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Rodríguez MM, Onorato A, Cantero MJ, et al. 4-methylumbelliferone-mediated polarization of M1 macrophages correlate with decreased hepatocellular carcinoma aggressiveness in mice. Sci Rep. 2021;11(1):6310. DOI:10.1038/s41598-021-85491-0</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Vitale DL, Icardi A, Rosales P, et al. Targeting the Tumor Extracellular Matrix by the Natural Molecule 4-Methylumbelliferone: A Complementary and Alternative Cancer Therapeutic Strategy. Front Oncol. 2021;11:710061. DOI:10.3389/fonc.2021.710061</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Kakizaki I, Takagaki K, Endo Y, et al. Inhibition of hyaluronan synthesis in Streptococcus equi FM100 by 4-methylumbelliferone. Eur J Biochem. 2002;269(20):5066-75. DOI:10.1046/j.1432-1033.2002.03217.x</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Jong A, Wu CH, Chen HM, et al. Identification and characterization of CPS1 as a hyaluronic acid synthase contributing to the pathogenesis of Cryptococcus neoformans infection. Eukaryot Cell. 2007;6(8):1486-96. DOI:10.1128/EC.00120-07</mixed-citation></ref><ref id="B61"><label>61.</label><mixed-citation>Yoshioka Y, Kozawa E, Urakawa H, et al. Suppression of hyaluronan synthesis alleviates inflammatory responses in murine arthritis and in human rheumatoid synovial fibroblasts. Arthritis Rheum. 2013;65(5):1160-70. DOI:10.1002/art.37861</mixed-citation></ref><ref id="B62"><label>62.</label><mixed-citation>Mueller AM, Yoon BH, Sadiq SA. Inhibition of hyaluronan synthesis protects against central nervous system (CNS) autoimmunity and increases CXCL12 expression in the inflamed CNS. J Biol Chem. 2014;289(33):22888-99. DOI:10.1074/jbc.M114.559583</mixed-citation></ref><ref id="B63"><label>63.</label><mixed-citation>Nagy N, Kaber G, Sunkari VG, et al. Inhibition of hyaluronan synthesis prevents β-cell loss in obesity-associated type 2 diabetes. Matrix Biol. 2023;123:34-47. DOI:10.1016/j.matbio.2023.09.003</mixed-citation></ref><ref id="B64"><label>64.</label><mixed-citation>Al-Majedy YK, Al-Amiery AA, Kadhum AA, Mohamad AB. Antioxidant Activities of 4-Methylumbelliferone Derivatives. PLoS One. 2016;11(5):e0156625. DOI:10.1371/journal.pone.0156625</mixed-citation></ref><ref id="B65"><label>65.</label><mixed-citation>Lin Z, Cheng X, Zheng H. Umbelliferon: a review of its pharmacology, toxicity and pharmacokinetics. Inflammopharmacology. 2023;31(4):1731-50. DOI:10.1007/s10787-023-01256-3</mixed-citation></ref><ref id="B66"><label>66.</label><mixed-citation>Tsitrina AA, Halimani N, Andreichenko IN, et al. 4-Methylumbelliferone Targets Revealed by Public Data Analysis and Liver Transcriptome Sequencing. Int J Mol Sci. 2023;24(3):2129. DOI:10.3390/ijms24032129</mixed-citation></ref><ref id="B67"><label>67.</label><mixed-citation>Li T, Francl JM, Boehme S, Chiang JY. Regulation of cholesterol and bile acid homeostasis by the cholesterol 7α-hydroxylase/steroid response element-binding protein 2/microRNA-33a axis in mice. Hepatology. 2013;58(3):1111-21. DOI:10.1002/hep.26427</mixed-citation></ref><ref id="B68"><label>68.</label><mixed-citation>Xing X, Burgermeister E, Geisler F, et al. Hematopoietically expressed homeobox is a target gene of farnesoid X receptor in chenodeoxycholic acid-induced liver hypertrophy. Hepatology. 2009;49(3):979-88. DOI:10.1002/hep.22712</mixed-citation></ref><ref id="B69"><label>69.</label><mixed-citation>Gupta S, Stravitz RT, Dent P, Hylemon PB. Down-regulation of cholesterol 7alpha-hydroxylase (CYP7A1) gene expression by bile acids in primary rat hepatocytes is mediated by the c-Jun N-terminal kinase pathway. J Biol Chem. 2001;276(19):15816-22. DOI:10.1074/jbc.M010878200</mixed-citation></ref><ref id="B70"><label>70.</label><mixed-citation>Chiang JYL, Ferrell JM. Up to date on cholesterol 7 alpha-hydroxylase (CYP7A1) in bile acid synthesis. Liver Res. 2020;4(2):47-63. DOI:10.1016/j.livres.2020.05.001</mixed-citation></ref></ref-list></back></article>
